Lyell Stock

lyellbiotech.comHealthcareFounded: 2018Funding to Date: $358MM

Lyell Immunopharma is a developer of curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.

Register for Details

For more details on financing and valuation for Lyell, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Lyell.

Register Today

Team

Management Team

Premal Patel MD
Chief Medical Officer
Akira Matsuno
Chief Financial Officer & Head of Corporate Development
Richard Klausner MD
Founder, President, Board Member & Chief Executive Officer

Board Members

Richard Klausner MD
Robert Nelsen
ARCH Venture Partners
Cathy Friedman
Hans Bishop

Other companies like Lyell in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM